Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders (May 2014)

by Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Russell Katz, Vincenzo Di Marzo, Didier Jutras‐Aswad, William George Notcutt, Jose Martinez‐Orgado, Philip J. Robson, Brian G. Rohrback, Elizabeth Thiele, Benjamin Whalley, Daniel Friedman.

 The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G‐protein‐coupled receptor GPR55; the transient receptor potential of vanilloid type‐1 channel; the 5‐HT1a receptor; and the α3 and α1 glycine receptors. CBD has neuroprotective and antiinflammatory effects, and it appears to be well tolerated in humans, but small and methodologically limited studies of CBD in human epilepsy have been inconclusive. More recent anecdotal reports of high‐ratio CBD:Δ9‐THC medical marijuana have claimed efficacy, but studies were not controlled. CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic‐ischemic encephalopathy. 

Find the article from Epilepsia here:

Related Posts

Leave a Reply